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Background: The incidence of metabolic syndrome (MetS), diabetes mellitus (DM) and their coexistence is increasing, but whether MetS 
represents a synergistic increase in CV risk beyond component risk factors (RF) is controversial.
Methods: We set out to compare 4-yr risk for CV death/MI/stroke in patients (pts) w/ MetS, newly recognized DM, prior DM or coexistent MetS/
DM to pts w/o MetS or DM independent of traditional RF, subclinical atherothrombosis or prior ischemic events in the international outpatient 
REACH Registry (n=45,227 with 4-yr follow-up).
Results: Among the 36,682 eligible REACH pts, 34% were without MetS or DM at baseline (n=12,710), 16% had MetS w/o DM (n=5,877), 1.8% 
new DM (n=645), 28% prior DM (n=10,187) and 20% had both MetS + DM (n=7,263). Cumulative 4-yr rates of CV death/MI/stroke are shown in 
the figure. The risk of mortality and CV death were consistent with these observations; pts with new DM had highest risk while pts with MetS had no 
significant increased risk. After further adjustment for CV RF and baseline statin/aspirin use, the risk of the composite endpoint for pts w/ new DM 
was attenuated (HR 1.25 [0.97-1.61]) but remained significant in those with prior DM and both MetS/DM. However, new DM pts remained at high 
risk of mortality (HR 1.76 [1.34-2.31]) and CV death (1.77 [1.25-2.52]) similar to pts with prior DM or MetS/DM.
Conclusion: In REACH, the presence of MetS did not confer higher risk for future CVD in pts with or without DM. Pts w/ newly recognized DM had 
high risk for future CV events.
 
